

UC Davis

UC Davis Previously Published Works

Title

Plasma fatty acid ethanolamides are associated with postprandial triglycerides, ApoCIII, and ApoE in humans consuming a high-fructose corn syrup-sweetened beverage

Permalink

<https://escholarship.org/uc/item/2m956334>

Journal

AJP Endocrinology and Metabolism, 315(2)

ISSN

0193-1849

Authors

Price, Candice Allister

Argueta, Donovan A

Medici, Valentina

et al.

Publication Date

2018-08-01

DOI

10.1152/ajpendo.00406.2017

Peer reviewed

1 **Plasma fatty acid ethanolamides are associated with postprandial triglycerides, ApoCIII and ApoE in**
2 **humans consuming high fructose corn syrup (HFCS)-sweetened beverage.**

3 Candice (Allister) Price¹, Donovan A. Argueta⁴, Valentina Medici³, Andrew A. Bremer², Vivien Lee¹, Marinelle V.
4 Nunez¹, Guoxia X. Chen¹, Nancy L. Keim², Peter J. Havel¹, Kimber L. Stanhope¹, Nicholas V. DiPatrizio^{5*}.

5
6 ¹ From the Department of Molecular Biosciences, School of Veterinary Medicine (CAP, KLS, VL, HDL, GXC,
7 and PJH), the Department of Nutrition (KLS, MVN, NLK, and PJH)

8
9 ² the Division of Gastroenterology and Hepatology, School of Medicine (VM), and the Department of Pediatrics,
10 School of Medicine, University of California, Davis, Davis, CA (AAB).

11
12 ³US Department of Agriculture, Western Human Nutrition Research Center, Davis, CA (NLK).

13
14 ⁴Division of Biomedical Sciences, School of Medicine, University of California Riverside, Riverside, California.

15

16 *Corresponding author: Nicholas DiPatrizio, 900 University Avenue, University of California Riverside School
17 of Medicine, Riverside CA, 92521. Email: ndipatri@medsch.ucr.edu.

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36 **Abstract**

37 Epidemiological and clinical research studies have provided ample evidence demonstrating that consumption of
38 sugar-sweetened beverages (SSB) increases risk factors involved in the development of obesity, type 2 diabetes
39 (T2D), and cardiovascular disease (CVD). Our previous study demonstrated that when compared to aspartame
40 (Asp), two weeks of high-fructose corn syrup (HFCS)-sweetened beverages provided at 25% of daily energy
41 requirement (Ereq) was associated with increased body weight, postprandial (pp) triglycerides (TG), and fasting
42 and pp CVD risk factors in young adults. The fatty acid ethanolamide, anandamide (AEA), and the
43 monoacylglycerol, 2-arachidonoyl-*sn*-glycerol (2-AG), are two primary endocannabinoids (ECs) that play a role
44 in regulating food intake, increasing adipose storage, and regulating lipid metabolism. Therefore, we measured
45 plasma concentrations of ECs and their analogs, oleoylethanolamide (OEA), docosahexaenoyl ethanolamide
46 (DHEA), and docosahexaenoyl glycerol (DHG), in participants from our previous study who consumed HFCS- or
47 Asp-sweetened beverages to determine associations with weight gain and CVD risk factors. Two-week exposure
48 to either HFCS- or Asp-sweetened beverages resulted in significant differences in the changes in fasting levels of
49 OEA and DHEA between groups after the testing period. Subjects who consumed Asp, but not HFCS, displayed
50 a reduction in AEA, OEA and DHEA after the testing period. In contrast, there were significant positive
51 relationships between AEA, OEA, and DHEA versus ppTG, ppApoCIII and ppApoE in those consuming HFCS,
52 but not in those consuming Asp. Our findings reveal previously unknown associations between circulating ECs
53 and EC-related molecules with markers of lipid metabolism and CVD risk after HFCS-consumption.

54

55 **Keywords:** High-fructose corn syrup, anandamide (AEA), oleoylethanolamide (OEA), ApoCIII, ApoE,
56 triglycerides (TG)

57

58

59

60

61

62 **Introduction**

63 High consumption of sugar-sweetened beverages (SSB) is a leading contributing factor to the obesity epidemic,
64 type 2 diabetes (T2D), and cardiovascular disease (CVD) (9, 20, 24, 25, 38). Consumption of fructose-
65 containing beverages is associated with increases in body weight and CVD lipid markers, and decreases insulin
66 sensitivity (1, 36, 40). Sugar-sweetened beverages in the U.S. commonly contain high fructose corn syrup
67 (HFCS) with fructose content ranging from 47 to 65% (43). We previously reported that subjects consuming 0,
68 10, 17.5 and 25% Ereq as HFCS-sweetened beverages exhibited a dose-dependent increase in body weight in two
69 weeks (39), and large dose-dependent increases in postprandial (pp)triglycerides (TG), fasting and pp low-
70 density lipoprotein (ppLDL), pp ApolipoproteinB (ppApoB), ApolipoproteinCIII (ppApoCIII), and uric acid.
71 Therefore, fructose-containing beverages may contribute to increased metabolic risk via both weight gain and
72 upregulation of hepatic lipid production (38); however, specific roles for the endocannabinoid system in these
73 processes are largely unknown. Nonetheless, a small number of studies suggest that endocannabinoids (ECs) –
74 which are signaling molecules known to regulate both food intake (4, 10, 11, 17, 29) and lipid metabolism (30,
75 37) (8, 32) – may play a role in metabolic dysregulation induced by fructose-containing beverages. (17, 23).

76 Two primary ECs, the fatty acid ethanolamide anandamide (AEA) and the monoacylglycerol 2-arachidonoyl-*sn*-
77 glycerol (2-AG), act through cannabinoid type 1 receptors (CB₁R) to stimulate palatable food intake (4, 5, 13, 14,
78 22). This is in contrast to oleoylethanolamide (OEA), a related fatty acid ethanolamide analog of AEA that does
79 not interact with the CB receptors and plays a role in suppressing food intake (11, 12, 18, 19, 34). Other less-
80 studied analogs of ECs including the fatty acid ethanolamide, docosahexaenoyl ethanolamide (DHEA), and the
81 monoacylglycerol, docosahexaenoyl glycerol (DHG), may stimulate glucose uptake *in vitro* (21) and have anti-
82 inflammatory properties (15, 33); however, a comprehensive understanding of their physiological roles is lacking.

83 Our primary objective of this study was to determine if two weeks of HFCS-sweetened beverage consumption
84 impacts plasma concentrations of ECs or their analogs. We hypothesized that two weeks of HFCS-sweetened
85 beverage consumption would be associated with increases in plasma levels of appetite-stimulating AEA and 2-
86 AG, and decreased levels of appetite-suppressing OEA. A secondary objective was to determine if changes in

87 AEA, 2-AG, or their analogs are associated with changes in body weight and lipids/lipoproteins in subjects
88 consuming HFCS for two weeks.

89 **Methods**

90 *Study participants*

91 Participants in this study are a subgroup from an NIH-funded investigation in which a total of 187 participants
92 assigned to 8 experimental groups were studied, as previously described (39). The current article reports the
93 results from 49 subjects consuming beverages containing either 0% ($n=21$) or 25% ($n=28$) daily energy
94 requirement (Ereq) from high fructose corn syrup (HFCS). The study was conducted in accordance with an
95 experimental protocol that was approved by the UC Davis Institutional Review Board, and participants provided
96 written informed consent.

97 Participants were recruited through an internet listing (craigslist.com) and local postings of flyers, and underwent
98 telephone and in-person screenings with medical history, completed blood count and serum biochemistry panel to
99 assess eligibility. Inclusion criteria included age 18-40 yrs, BMI 18-35 kg/m² with self-report of stable body
100 weight during the prior 6 months. Exclusion criteria included diabetes (fasting glucose >125 mg/dL), evidence of
101 renal or hepatic disease, fasting plasma triglyceride >400 mg/dL, hypertension (>140/90 mm Hg), hemoglobin
102 <8.5 g/dL, and surgery for weight loss. Individuals who smoked, habitually ingested >2 alcoholic beverages/d,
103 exercised >3.5 hr/week at a level more vigorous than walking, or used thyroid, lipid-lowering, glucose-lowering,
104 antihypertensive, antidepressant, or weight loss medications were also excluded. Assignment to experimental
105 groups were not randomized; by design, the experimental groups were matched for sex, BMI, and concentrations
106 of fasting triglyceride, cholesterol, HDL cholesterol and insulin in plasma collected during the in-person
107 interviews.

108 For the 5 weeks prior to the start of the study, subjects who were scheduled for participation were asked to limit
109 daily consumption of sugar-containing beverages to no more than one 237ml serving of fruit juice and discontinue
110 consumption of any vitamin, mineral, herbal, or dietary supplements, including fish oil. A total of 55 subjects

111 were enrolled in experimental groups consuming either 0% (aspartame (Asp)) or 25% Ereq-HFCS. Two subjects
112 withdrew from the study before the start of intervention, and four additional subjects withdrew for various reasons
113 previously reported (39). A total of 51 subjects completed the study with 23 subjects in the Asp group and 28 in
114 the HFCS group. Due to the unavailability of samples for two of the Asp subjects, results reported here include a
115 total of 21 subjects in this group.

116 *Study Design*

117 This was a parallel-arm, double-blinded diet intervention study with 3 phases: 1) a 3.5-day inpatient baseline
118 period during which subjects resided at the University of California Davis Clinical and Translational Science
119 Center's Clinical Research Center (CCRC), consumed a standardized baseline diet, and participated in
120 experimental procedures; 2) a 12-day outpatient in intervention period during which subjects consumed their
121 assigned sweetened beverages providing 0% (Asp-sweetened) or 25% Ereq-HFCS along with their usual ad
122 libitum diets; and 3) a 3.5-day inpatient intervention period during which subjects resided at the CCRC and
123 consumed standardized diets that included the sweetened beverages, and all experimental procedures were
124 repeated.

125 *Inpatients diets*

126 During days 2 and 3 of the baseline and intervention inpatient periods, subjects consumed energy-balanced meals
127 consisting of conventional foods. Daily Ereq were calculated by the Mifflin equation (28), with adjustment of 1.3
128 for activity on the days of the 24-hour serial blood collections and adjustment of 1.5 for the other days. The
129 baseline diet contained 55% Ereq mainly as low-fiber complex carbohydrate (i.e. white bread, white rice, regular
130 pasta), 30% from fat, and 15% from protein. The meals during the inpatient intervention period included that
131 assigned study beverages and were as identical as possible to baseline meals, except for the substitution of the
132 sugar-sweetened beverage in place of isocaloric amounts of complex carbohydrate. The intervention meals
133 contained 19-20 g fiber/2000 kcal fiber, and the baseline meals contained 22 g fiber/2000 kcal. The timing of

134 inpatient meals and the energy distribution were as follows: breakfast, 0900 (25%); lunch, 1300 (35%); and
135 dinner, 1800 (40%).

136 *Study beverages and outpatient diet*

137 HFCS-containing beverages were sweetened with HFCS-55 (Isosweet 5500, 55% fructose, 45% glucose:
138 Skidmore Sales and Distributing), flavored with an unsweetened drink mix (Kool-Aid; Kraft Inc.). A fruit-
139 flavored aspartame drink mix (Market Pantry) was used to prepare the 0% Ereq-HFCS beverages. Participants
140 were blinded to their beverage assignment, as were all CCRC and study personnel who interacted with
141 participants or analyzed samples. Voluntary feedback from participants indicated that they were able to
142 distinguish between beverages containing aspartame (Asp) or HFCS. The amount (grams) of beverage provided
143 was standardized among the 2 groups and based on energy requirements [calculated with the Mifflin equation
144 (28), plus 1.5 activity adjustment]. During the 12-day outpatient phase of the study, participants were instructed
145 to drink one serving of study beverage with each meal, to consume their usual diet, and to not consume other
146 sugar-sweetened beverages, including fruit juice. To monitor compliance of beverage consumption (35, 41), the
147 study beverages contained a biomarker (riboflavin) that was measured fluorimetrically in urine samples collected
148 that times of beverage pickup. Subjects were informed about the biomarker but were not provided information
149 regarding its identify. Fasting urinary riboflavin concentrations following days 9 and 13 of unmonitored beverage
150 consumption were not different from those following one day of monitored beverage consumption at the CCRC,
151 suggesting good and comparable compliance in all groups (39).

152 *Fasting blood collection and lipid analysis*

153 Fasting blood samples reported here were collected at 0800 hr and stored at -80°C for the measurement of
154 triglycerides (TG), apolipoprotein C III (ApoCIII), apolipoprotein E (ApoE), and EC-related outcomes. EC-related
155 outcomes included monoacylglycerols (MAGs) [docosahexaenoyl glycerol (DHG) and 2-arachidonoyl-*sn*-glycerol
156 (2-AG)] and fatty acid ethanolamides (FAEs) [anandamide (AEA), oleoylethanolamide (OEA), and
157 docosahexaenoyl ethanolamide (DHEA)]. Lipid extraction and analysis of MAGs and FAEs were performed as

158 previously described (4). Plasma (0.5 mL) was added to 1.0 mL of methanol solution containing the internal
159 standards, [$^3\text{H}_i$]-2-AG, [$^3\text{H}_i$]-AEA, and [$^3\text{H}_i$]-OEA (Cayman Chemical, Ann Arbor, MI, USA). Lipids were extracted
160 with chloroform (2 mL) and washed with 0.9 % saline (0.5 mL). Organic phases were collected and separated by
161 open-bed silica gel column chromatography. Eluate was gently dried under N_2 stream (99.998% pure) and
162 resuspended in 0.1 mL of methanol:chloroform (9:1), with 1 μL injection for ultra-performance liquid
163 chromatography/tandem mass spectrometry (UPLC/MS/MS) analysis.

164 Lipids were analyzed using a Waters Acquity I-Class Ultra Performance Liquid Chromatography system coupled
165 to a Waters TQS-micro Triple Quadrupole Mass Spectrometer. Lipids were separated using an Acquity UPLC
166 BEH C18 column (50 x 2.1 mm; i.d. 1.7 μm), eluted by a gradient of methanol (0.25% acetic acid, 5mM
167 ammonium acetate) in water (0.25% acetic acid, 5mM ammonium acetate) (from 80 to 100% methanol in 2.5
168 min, 100% 2.5-3.0 min, 100-80% 3.0-3.1 min) at a flow rate of 0.4 mL/min. Column temperature was kept at 40°
169 C and samples were maintained in the sample manager at 10° C. Argon was used as collision gas (99.998% pure).
170 2-AG, AEA, OEA, DHG, DHEA, [$^3\text{H}_i$] 2-AG, [$^3\text{H}_i$] AEA, and [$^3\text{H}_i$] OEA were identified in the positive ionization
171 mode based on their retention times and MS^2 properties. Lipids were quantified using a stable isotope dilution
172 method detecting protonated adducts of the molecular ions $[\text{M}+\text{H}]^+$ in the multiple reaction monitoring (MRM)
173 mode. Extracted ion chromatograms were used to quantify 2-AG ($m/z = 379.2 > 287.26$), AEA ($m/z =$
174 $348.3 > 62.04$), OEA ($m/z = 326.3 > 62.08$), DHG ($m/z = 403.3 > 311.19$), DHEA ($m/z = 372.3 > 91.02$), and [$^3\text{H}_i$] 2-
175 AG ($m/z = 384.2 > 93.4$), [$^3\text{H}_i$] AEA ($m/z = 352.3 > 66.11$), and [$^3\text{H}_i$] OEA ($m/z = 330.3 > 66.05$), which were used as
176 internal standards (Cayman Chemical, Ann Arbor, MI, USA; [$^3\text{H}_i$] 2-AG as internal standard for 2-AG and DHG;
177 [$^3\text{H}_i$] AEA ($m/z = 352.3 > 66.11$) as internal standard for AEA and DHEA; [$^3\text{H}_i$] OEA as internal standard for OEA).

178 *Postprandial lipid measurements*

179 Postprandial measures of total triglycerides (TG), apolipoprotein C III (ApoCIII), and apolipoprotein E (ApoE)
180 were collected at time points 2200, 2300 and 2400 hr because this was the period during which peak ppTG
181 concentrations were observed in our previous study (40). These 3 late-night pp plasma samples were pooled

182 together and multiple aliquots of each pooled sample were stored at -80°C. Lipid and lipoprotein concentrations
183 were measured with a Polychem Chemistry Analyzer (PolyMedCo Inc.) with reagents from MedTest DX.

184 *Statistical analyses*

185 Baseline anthropometric and clinical characteristics were compared between 0% Ereq (Asp) and 25% HFCS
186 groups using a student t-test. The percent change (% Δ) of these measures from 0-wk to 2-wk of intervention was
187 compared using a general linear model (SAS 9.4), with % Δ outcome value at week 2 as the categorical variable,
188 adjusting for sex and change in BMI, as well as sex x group interactions. Secondary analyses of absolute values
189 at 0-wk and 2-wk were analyzed by repeated measures ANCOVA, testing for an interaction between beverage
190 group and time. By group univariate linear regressions were conducted to determine potential relationships
191 between changes in EC-related compounds and fasting or pp-lipids measures. Data presented in Table 1 are
192 means \pm SDs; all other data are means \pm SEMs.

193

194 **Results**

195 *Baseline characteristics and post-intervention lipid markers of CVD*

196 Baseline anthropometric and metabolic outcomes were not significantly different between groups (**Table 1**).
197 Amongst the ECs at baseline, plasma concentrations of AEA, 2-AG and the related DHG, did not differ; however,
198 OEA and DHEA were significantly higher in the aspartame group (**Table 2**). This difference was driven by 2
199 outliers in the Asp group. Sensitivity analyses and re-analyses of EC-related compounds with removal of these 2
200 outliers revealed that baseline differences between groups were not significant (**Table 2**), and % Δ at intervention
201 was only moderately affected (**Figures 1 and 2**). Therefore, these outliers remained included in analyses;
202 however, we included significance values with and without these outliers in all figures. Body weight, ppApoE,
203 and fasting and pp TG and ApoCIII were all significantly increased in subjects consuming HFCS for two weeks
204 when compared to Asp controls (**Table 3**).

205

206 *Changes in circulating ECs and their analogs after two weeks of SSB*
207 Significant beverage x time interactions were found for OEA (p=0.03) and DHEA (p=0.008), and a trending
208 interaction for AEA (p=0.08) (**Figure 1**). **Figure 2** presents these differences between groups as % Δ from
209 baseline by ANCOVA analyses. There were no differences between groups in the % Δ in 2-AG (p=0.83) or DHG
210 (p=0.74). Including an adjustment for sex revealed a near-significant effect of sex on % Δ in AEA (p=0.06);
211 however, there were no significant sex x beverage interactions on EC-related outcomes. Paired *t*-tests were
212 conducted for within beverage group comparisons of values at baseline versus week 2 of intervention.
213 Consumption of HFCS-sweetened beverage for two weeks did not result in changes in the plasma levels of the
214 ECs and their analogs. Participants consuming Asp, however, exhibited significant reductions in the fatty acid
215 ethanolamides, AEA (p= 0.01), OEA (p= 0.008), and DHEA (p= 0.001) (**Figure 1**).

216

217 *Differential associations between Asp versus HFCS beverages in their relationships of AEA, OEA, DHEA with*
218 *CVD lipid markers*

219 Absolute changes in ECs and their analogs did not correlate with change in body weight or BMI in either group,
220 with the exception of OEA, which showed a weak relationship with change in body weight in the HFCS group
221 (r=0.11, p=0.02) (data not shown). Linear regression analyses revealed differences between beverage groups in
222 the relationships between changes in lipid and EC-related outcomes. There was no relationship between AEA and
223 fasting lipid outcomes in either group (**Figure 3A-C**). Negative relationships were found between Δ OEA and Δ
224 fasting TG (r= 0.20, p= 0.04) in the Asp group; however, the HFCS group trended towards a positive relationship
225 (r= 0.10, p= 0.09) (**Figure 3 D**). The relationship between Δ OEA and Δ fasting ApoCIII did not reach
226 significance in either beverage group (Asp r= 0.14, p= 0.11; HFCS r= 0.18, p= 0.07) (**Figure 3E**). In the Asp
227 group, a trend was observed between Δ OEA and Δ fasting ApoE (r= 0.18, p= 0.07) (**Figure 3F**), but no
228 relationship was present within the HFCS group. The strongest relationships under fasting conditions were
229 observed in the Asp group between Δ DHEA and Δ TG (r= 0.26, p= 0.005), Δ ApoCIII (r= 0.47, p= 0.001), and Δ

230 ApoE ($r=0.24$, $p=0.03$) (**Figure 3 G-I**). Change in DHEA did not correlate to any of the lipid outcomes in the
231 HFCS group under fasting conditions.

232 Under pp conditions, relationships between lipids and ECs were only present in those consuming HFCS. In the
233 HFCS group, Δ AEA correlated positively with Δ ppTG ($r=0.26$, $p=0.006$) and Δ ppApoCIII ($r=0.29$, $p=0.020$)
234 (**Figure 4A and B**). Changes in OEA were positively related to Δ ppTG, Δ ppApoCIII and Δ ppApoE in those
235 consuming HFCS, with the strongest relationship being with the change in Δ ppApoCIII ($r=0.53$, $p<0.0001$)
236 (**Figure 4D-F**). This differed from changes in DHEA, which only showed a weak relationship with changes in Δ
237 ppApoCIII ($r=0.17$, $p=0.03$) and no relationship with either Δ ppTG or Δ ppApoE (**Figure 4G-H**). There were no
238 associations between pp lipids and the lipid-derived EC analogs in subjects consuming Asp beverage (**Figure 4**).

239

240 **Discussion**

241 This is the first study in humans to demonstrate an association between the EC system and increased CVD risk
242 factors in response to HFCS consumption. We hypothesized that two week consumption of HFCS-sweetened
243 beverage, when compared to Asp-sweetened beverage, would be associated with increased plasma levels of
244 appetite-stimulating AEA and 2-AG, and decreased appetite-suppressing OEA. Contrary to our hypotheses,
245 HFCS beverage in normal-weight adults was not associated with any significant changes in ECs and their
246 analogs; however, subjects consuming Asp beverage displayed decreases in levels of the fatty acid ethanolamides,
247 AEA, OEA, and DHEA. Furthermore, plasma levels of AEA, OEA, and DHEA were positively associated with
248 changes in ppTG, ppApoCIII and ppApoE in participants consuming HFCS, but not in those consuming Asp
249 beverage. These findings demonstrate an association between ECs and their analogs with markers of lipid
250 metabolism and CVD in response to sugar-sweetened beverage consumption.

251 Despite significant increases in body weight following the HFCS beverage intervention, ECs and their analogs were
252 not strongly associated with weight gain, with the exception of a weak relationship between Δ OEA and body

253 weight. This effect is possibly due to the short-term intervention resulting in modest weight gain rather than longer-
254 term interventions resulting in more clinically-significant weight gain. Nonetheless, the weak positive correlation
255 is in line with findings of higher plasma OEA concentrations in obese compared to lean individuals (2, 26)..
256 Furthermore, Matias and colleagues (26) demonstrated that salivary OEA and AEA correlated with BMI, body
257 weight, and waist circumference in obese individuals.

258 In rodents, high-fat diet-induced obesity is associated with greater expression of hepatic CB₁ receptors through
259 which ECs may stimulate hepatic DNL (31), and high-fructose or -sucrose diets result in greater hypothalamic
260 synthesis of ECs and CB₁ receptor activity (17, 23). No associations were found when comparing plasma levels of
261 the ECs with TG, ApoCIII and ApoE in the fasted state in subjects consuming HFCS. In the pp state, however,
262 significant positive relationships were found between AEA and OEA versus TG and ApoCIII, and OEA versus
263 ApoE. This finding may suggest that ECs and related molecules did not affect TG and ApoCIII production, but
264 rather HFCS-induced increases in ppTG, ppApoCIII, and to a lesser extent ppApoE, affected plasma levels of
265 AEA, OEA and DHEA. This result may be a threshold effect, however, because increases in ECs and their
266 analogs were observed mainly in the subjects who exhibited higher increases in ppTG, ppApoCIII and ppApoE.
267 HFCS-induced increases in TG, ApoCIII and ApoE were approximately twice as high in the pp state than the
268 fasting state,; thus, a positive relationship between ECs and TG/lipoproteins was apparent only in the pp state.

269 Consumption of asp-sweetened beverages was associated with reduced fasting concentrations of plasma AEA,
270 OEA, and DHEA. Whether reductions in appetite-stimulating AEA in the absence of changes in body weight is a
271 result of the presence of Asp, or in contrast, the absence of SSB, requires further study. Understanding this
272 relationship could have implications for interventions aimed at reducing food intake and body weight since. Indeed,
273 Asp beverage consumption has been shown to lower caloric intake and reduce desire for highly palatable foods (3),
274 and reductions in salivary AEA were found following a three-month weight loss intervention (16, 26).

275 Reductions in DHEA, AEA, and OEA in Asp-consuming subjects may also reflect a decrease in inflammatory
276 responses (27). DHEA, AEA, and possibly OEA have been implicated in anti-inflammatory responses (7, 42, 44),
277 and share common fatty acid ethanolamide biosynthetic and degradative pathways (12, 18, 19, 34). The EC, 2-AG,

278 is a monoacylglycerol (30) that is also synthesized from AA (similar to AEA) and plays a role in inflammation, but
279 our results suggests that only fatty acid ethanolamides are associated with Asp consumption. Further studies are
280 needed to better understand the biological relevance of the Asp-associated reduction in fatty acid ethanolamides in
281 the context of, both, appetite regulation and anti-inflammatory responses.

282 To our knowledge, this is the first study to examine the effects of HFCS beverage consumption on circulating
283 ECs, and importantly, in healthy, non-obese individuals. Nonetheless, this study has several limitations.
284 Participants consumed ad libitum diets during the 12-day outpatient period, thus we did not control for precise
285 quantities of sugars consumed. Nonetheless, our study participants were instructed to abstain from consuming
286 outside beverages containing added sugar, but were not instructed to abstain from naturally-occurring sugars such
287 as those found in fruits, which also contain antioxidants and polyphenols. Unlike natural sources of sugar, added
288 sugars consumed as sweetened beverages provide little to no nutritional value. Therefore, we did not feel it
289 necessary to restrict participants from consuming natural, nutritional food items and did not have prior evidence to
290 suggest that this would impact the outcomes of this study. Similarly, participants were instructed to cease intake
291 of fish oil supplements five weeks prior to and during the study, as these supplements have been shown to alter
292 levels of DHEA, DHA, and ECs (6). Although participants were not prohibited from consuming fish during the
293 study, it is unlikely that fish intake was greater in one group over the other as there is no prior evidence to suggest
294 that Asp or HFCS influences the desire to eat foods high in omega fatty acids. Another limitation to our study is
295 that ECs and their analogs were measured only in fasting plasma. Future studies that include postprandial EC
296 measures will provide valuable insight into the heterogeneous functions (e.g. regulation of appetite signaling and
297 lipid metabolism) of AEA, OEA, and DHEA in response to a HFCS beverage. In addition, saliva measures of
298 ECs would better assess whether or not increases in ECs can explain taste-related links between SSB, hedonic
299 feeding behavior, and weight-gain in humans.

300 **Conclusion**

301 This is the first study to demonstrate the effects of Asp- and HFCS-sweetened beverage consumption on
302 circulating ECs in humans. The unexpected absence of an effect of HFCS on the EC system in this study should

303 be further investigated under longer-term exposure to HFCS and in response to a meal. On the contrary, observed
304 effects of Asp on circulating ECs raise questions regarding the potential effects of artificial sweeteners on food-
305 reward pathways and should be further explored. Lastly, our study shows differential effects of beverage type on
306 circulating EC compounds in relationship to lipid risk factors of CVD in the fasted and postprandial states. Future
307 studies are needed to further understand the possible implications this may have on metabolic functions.

308

309

310

311

312

313

314

315

316

317

318

319

320 **References**

- 321 1. **Aeberli I, Zimmermann MB, Molinari L, Lehmann R, l'Allemand D, Spinaz GA, and Berneis K.** Fructose
322 intake is a predictor of LDL particle size in overweight schoolchildren. *Am J Clin Nutr* 86: 1174-1178, 2007.
- 323 2. **Annucci G, Piscitelli F, Di Marino L, Patti L, Giacco R, Costabile G, Bozzetto L, Riccardi G, Verde R,**
324 **Petrosino S, Rivellese AA, and Di Marzo V.** Differential alterations of the concentrations of endocannabinoids
325 and related lipids in the subcutaneous adipose tissue of obese diabetic patients. *Lipids Health Dis* 9: 43, 2010.
- 326 3. **Anton SD, Martin CK, Han H, Coulon S, Cefalu WT, Geiselman P, and Williamson DA.** Effects of stevia,
327 aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels. *Appetite* 55: 37-43,
328 2010.
- 329 4. **Argueta DA, and DiPatrizio NV.** Peripheral endocannabinoid signaling controls hyperphagia in western
330 diet-induced obesity. *Physiol Behav* 171: 32-39, 2017.
- 331 5. **Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, and Le Fur G.** Selective
332 inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.
333 *Psychopharmacology (Berl)* 132: 104-106, 1997.
- 334 6. **Balvers MG, Verhoeckx KC, Bijlsma S, Rubingh CM, Meijerink J, Wortelboer HM, and Witkamp RF.** Fish
335 oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes in
336 mouse plasma and tissues. *Metabolomics* 8: 1130-1147, 2012.

- 337 7. **Balvers MG, Verhoeckx KC, Plastina P, Wortelboer HM, Meijerink J, and Witkamp RF.** Docosahexaenoic
338 acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl ethanolamines with anti-
339 inflammatory properties. *Biochim Biophys Acta* 1801: 1107-1114, 2010.
- 340 8. **Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-
341 Reineke C, Ortman S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, and Pagotto
342 U.** The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral
343 lipogenesis. *J Clin Invest* 112: 423-431, 2003.
- 344 9. **de Koning L, Malik VS, Kellogg MD, Rimm EB, Willett WC, and Hu FB.** Sweetened beverage
345 consumption, incident coronary heart disease, and biomarkers of risk in men. *Circulation* 125: 1735-1741,
346 S1731, 2012.
- 347 10. **DiPatrizio NV, Astarita G, Schwartz G, Li X, and Piomelli D.** Endocannabinoid signal in the gut controls
348 dietary fat intake. *Proc Natl Acad Sci U S A* 108: 12904-12908, 2011.
- 349 11. **DiPatrizio NV, Joslin A, Jung KM, and Piomelli D.** Endocannabinoid signaling in the gut mediates
350 preference for dietary unsaturated fats. *FASEB J* 27: 2513-2520, 2013.
- 351 12. **DiPatrizio NV, and Piomelli D.** Intestinal lipid-derived signals that sense dietary fat. *J Clin Invest* 125:
352 891-898, 2015.
- 353 13. **DiPatrizio NV, and Simansky KJ.** Activating parabrachial cannabinoid CB1 receptors selectively
354 stimulates feeding of palatable foods in rats. *J Neurosci* 28: 9702-9709, 2008.
- 355 14. **Dipatrizio NV, and Simansky KJ.** Inhibiting parabrachial fatty acid amide hydrolase activity selectively
356 increases the intake of palatable food via cannabinoid CB1 receptors. *Am J Physiol Regul Integr Comp Physiol*
357 295: R1409-1414, 2008.
- 358 15. **Dotsey E, Ushach I, Pone E, Nakajima R, Jasinskas A, Argueta DA, Dillon A, DiPatrizio N, Davies H,
359 Zlotnik A, Crompton PD, and Felgner PL.** Transient Cannabinoid Receptor 2 Blockade during Immunization
360 Heightens Intensity and Breadth of Antigen-specific Antibody Responses in Young and Aged mice. *Sci Rep* 7:
361 42584, 2017.
- 362 16. **Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC,
363 Sharma AM, and Jordan J.** Activation of the peripheral endocannabinoid system in human obesity. *Diabetes* 54:
364 2838-2843, 2005.
- 365 17. **Erlanson-Albertsson C, and Lindqvist A.** Fructose affects enzymes involved in the synthesis and
366 degradation of hypothalamic endocannabinoids. *Regul Pept* 161: 87-91, 2010.
- 367 18. **Fu J, Oveisi F, Gaetani S, Lin E, and Piomelli D.** Oleylethanolamide, an endogenous PPAR-alpha agonist,
368 lowers body weight and hyperlipidemia in obese rats. *Neuropharmacology* 48: 1147-1153, 2005.
- 369 19. **Hansen HS, and Vana V.** Non-endocannabinoid N-acylethanolamines and 2-monoacylglycerols in the
370 intestine. *Br J Pharmacol* 2018.
- 371 20. **Johnson RJ, Sanchez-Lozada LG, Andrews P, and Lanaspas MA.** Perspective: A Historical and Scientific
372 Perspective of Sugar and Its Relation with Obesity and Diabetes. *Adv Nutr* 8: 412-422, 2017.
- 373 21. **Kim J, Carlson ME, and Watkins BA.** Docosahexaenoyl ethanolamide improves glucose uptake and alters
374 endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts. *Front Physiol* 5:
375 100, 2014.
- 376 22. **Lau BK, Cota D, Cristino L, and Borgland SL.** Endocannabinoid modulation of homeostatic and non-
377 homeostatic feeding circuits. *Neuropharmacology* 124: 38-51, 2017.
- 378 23. **Lindqvist A, Baelemans A, and Erlanson-Albertsson C.** Effects of sucrose, glucose and fructose on
379 peripheral and central appetite signals. *Regul Pept* 150: 26-32, 2008.
- 380 24. **Malik VS, and Hu FB.** Sweeteners and Risk of Obesity and Type 2 Diabetes: The Role of Sugar-Sweetened
381 Beverages. *Curr Diab Rep* 2012.
- 382 25. **Malik VS, Schulze MB, and Hu FB.** Intake of sugar-sweetened beverages and weight gain: a systematic
383 review. *Am J Clin Nutr* 84: 274-288, 2006.

- 384 26. **Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G, Piazza PV, and Cota D.**
385 Endocannabinoids measurement in human saliva as potential biomarker of obesity. *PLoS One* 7: e42399, 2012.
- 386 27. **Meijerink J, Poland M, Balvers MG, Plastina P, Lute C, Dwarkasing J, van Norren K, and Witkamp RF.**
387 Inhibition of COX-2-mediated eicosanoid production plays a major role in the anti-inflammatory effects of the
388 endocannabinoid N-docosahexaenoyl ethanolamine (DHEA) in macrophages. *Br J Pharmacol* 172: 24-37, 2015.
- 389 28. **Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, and Koh YO.** A new predictive equation for
390 resting energy expenditure in healthy individuals. *Am J Clin Nutr* 51: 241-247, 1990.
- 391 29. **Monteleone AM, Di Marzo V, Monteleone P, Dalle Grave R, Aveta T, Ghoch ME, Piscitelli F, Volpe U,
392 Calugi S, and Maj M.** Responses of peripheral endocannabinoids and endocannabinoid-related compounds to
393 hedonic eating in obesity. *Eur J Nutr* 55: 1799-1805, 2016.
- 394 30. **Naughton SS, Mathai ML, Hryciw DH, and McAinch AJ.** Fatty Acid modulation of the endocannabinoid
395 system and the effect on food intake and metabolism. *Int J Endocrinol* 2013: 361895, 2013.
- 396 31. **Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K,
397 Offertaler L, Wang L, and Kunos G.** Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid
398 synthesis and contributes to diet-induced obesity. *J Clin Invest* 115: 1298-1305, 2005.
- 399 32. **Pagano C, Rossato M, and Vettor R.** Endocannabinoids, adipose tissue and lipid metabolism. *J*
400 *Neuroendocrinol* 20 Suppl 1: 124-129, 2008.
- 401 33. **Park T, Chen H, Kevala K, Lee JW, and Kim HY.** N-Docosahexaenoyl ethanolamine ameliorates LPS-
402 induced neuroinflammation via cAMP/PKA-dependent signaling. *J Neuroinflammation* 13: 284, 2016.
- 403 34. **Piomelli D.** A fatty gut feeling. *Trends Endocrinol Metab* 24: 332-341, 2013.
- 404 35. **Ramanujam VM, Anderson KE, Grady JJ, Nayeem F, and Lu LJ.** Riboflavin as an oral tracer for
405 monitoring compliance in clinical research. *Open Biomark J* 2011: 1-7, 2011.
- 406 36. **Schwarz JM, Noworolski SM, Wen MJ, Dyachenko A, Prior JL, Weinberg ME, Herraiz LA, Tai VW,
407 Bergeron N, Bersot TP, Rao MN, Schambelan M, and Mulligan K.** Effect of a High-Fructose Weight-Maintaining
408 Diet on Lipogenesis and Liver Fat. *J Clin Endocrinol Metab* 100: 2434-2442, 2015.
- 409 37. **Simon V, and Cota D.** MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past,
410 present and future. *Eur J Endocrinol* 176: R309-R324, 2017.
- 411 38. **Stanhope KL.** Sugar consumption, metabolic disease and obesity: The state of the controversy. *Crit Rev*
412 *Clin Lab Sci* 53: 52-67, 2016.
- 413 39. **Stanhope KL, Medici V, Bremer AA, Lee V, Lam HD, Nunez MV, Chen GX, Keim NL, and Havel PJ.** A
414 dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk
415 factors for cardiovascular disease in young adults. *Am J Clin Nutr* 101: 1144-1154, 2015.
- 416 40. **Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko**
417 **A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T,**
418 **Beysen C, Hellerstein MK, Berglund L, and Havel PJ.** Consuming fructose-sweetened, not glucose-sweetened,
419 beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. *J*
420 *Clin Invest* 119: 1322-1334, 2009.
- 421 41. **Switzer BR, Stark AH, Atwood JR, Ritenbaugh C, Travis RG, and Wu HM.** Development of a urinary
422 riboflavin adherence marker for a wheat bran fiber community intervention trial. *Cancer Epidemiol Biomarkers*
423 *Prev* 6: 439-442, 1997.
- 424 42. **Turcotte C, Chouinard F, Lefebvre JS, and Flamand N.** Regulation of inflammation by cannabinoids, the
425 endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. *J Leukoc Biol*
426 97: 1049-1070, 2015.
- 427 43. **Ventura EE, Davis JN, and Goran MI.** Sugar content of popular sweetened beverages based on objective
428 laboratory analysis: focus on fructose content. *Obesity (Silver Spring)* 19: 868-874, 2011.
- 429 44. **Yang L, Guo H, Li Y, Meng X, Yan L, Dan Z, Wu S, Zhou H, Peng L, Xie Q, and Jin X.** Oleoylethanolamide
430 exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPARalpha signaling and inhibiting the
431 NF-kappaB and ERK1/2/AP-1/STAT3 pathways. *Sci Rep* 6: 34611, 2016.

432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464

Figure Legends

Figure 1: Baseline and 2-wk EC and EC-related compound concentrations in Asp- or HFCS-sweetened beverage groups. Between-group comparisons were conducted by repeated measures analysis, and within group differences from baseline were conducted by *t*-test. Significance at $p < 0.05$. *p*-values in parentheses reflect significance after removal of 2 outliers in Asp group.

Figure 2: The percent change of endocannabinoids and their analogs in Asp and HFCS groups from 0-wk to 2-wk intervention. ANCOVA with adjustment for change in BMI; significance at $p < 0.05$. *p*-values in parentheses reflect significance after removal of 2 outliers in Asp group.

Figure 3: Linear regressions by beverage group comparing changes in AEA, OEA, DHEA versus changes in fasting TG, ApoCIII and ApoE. A through C, comparisons with Δ AEA; D through F, comparisons with Δ OEA; G through I, comparisons with Δ DHEA. ■ and solid line= HFCS; ▲ and dotted line=Asp.

Figure 4: Linear regressions by beverage group comparing changes in AEA, OEA, DHEA versus changes in postprandial TG, ApoCIII and ApoE. A through C, comparisons with Δ AEA; D through F, comparisons with Δ OEA; G through I, comparisons with Δ DHEA. ■ and solid line= HFCS; ▲ and dotted line=Asp.